Liver Disease Clinical Trial
Official title:
Evolution of Nutritional Status, Metabolic, Functional and Clinical Outcomes in Patients Undergoing Liver Transplantation
Liver transplantation (LTx) is the standard treatment used in the final stage of chronic or
acute liver failure. The success for the LT depends on many factors. One of the factors
related to morbidity and mortality of these patients is malnutrition. Patients on the
waiting list for LTx are increased risk of malnutrition and metabolic disorders that may be
associated with decreased functional capacity, change in resting energy expenditure cardiac
autonomic dysfunction. These conditions may influence the results both before and after
transplantation, as the clinical outcome and complications present in the postoperative
period. Therefore, this study aims to characterize and relate nutritional status, metabolic,
functional and clinical outcomes in the recent postoperative patients undergoing liver
transplantation. It is an observational, prospective study based on four evaluations: the
first will be conducted while the patient is awaiting transplantation; and after insertion
of the graft, patients will be evaluated between the 1nd and 3th postoperative day, between
5 and 7 days and at discharge from hospital.
In the late post-transplant, there is the action of immunosuppressive drugs, largely
responsible for increased survival, but also on the other hand, are responsible for
important nutritional and metabolic disorders. Metabolic complications such as hyperkalemia,
hypertension, diabetes mellitus and overweight have been described. Thus, due to the high
incidence of these complications, alternative options, such as lowering the dose of
immunosuppressive drugs, have been fully explored, particularly as regards association with
the viability of the graft. However, few studies have evaluated whether there is change in
the incidence of metabolic disorders, cited above, in relation to the different doses of
immunosuppressive drugs. Furthermore these metabolic complications will be evaluated in the
late post-transplant period.
This study was carried out at the Alfa Institute of Gastroenterology, Hospital of Clinics,
Universidade Federal of Minas Gerais (UFMG). The research protocol was approved by the UFMG
Ethics Committee. Patients with indication for liver transplantation, aged over 20 years who
regularly attended the Liver Outpatient Transplant Clinic were included after having agreed
and signed the informed consent form. Patients on the waiting list for a double or
re-transplant were excluding conditions.
Nutritional status was provided by the Subjective Global Assessment (SGA), adapted for
patients on the waiting list for liver transplantation is based on clinical history and
physical examination, as well as the presence of existing conditions such as encephalopathy,
chronic or recurrent infection, varicose veins and renal function.
Anthropometric evaluation was comprised of weight, height, body mass index (BMI), triceps
and subscapular skinfold thickness (TSF and SSF respectively, measured with the Lange
Skinfold Caliper - Cambridge Scientific Industries Inc., Cambridge, MD, USA), and arm muscle
area (AMA). To minimize practical variability, the average of three consecutive measurements
was recorded.
Functional parameters were evaluated by Handgrip strength (HS), 6-minute walk test (6MWT)
and heart frequency variability (HFV). HS was assessed with the Jamar Handgrip Dynamometer
(Preston, Jackson, MI, USA) using the non-dominant arm, and the mean of three measurements
was determined. The 6MWT was performed indoors, in a 30m long, flat corridor with an
adequate surface and the gait speed during the 6MWT was collected. The HRV was assessed
using short-term evaluation. The heart rate recording was acquired by RS800 CX (Polar,
Finland) and a 5-min stable cardiac recording was analyzed to assess the time domain (SD of
all normal-to-normal interval [SDNN]).
Bioelectrical impedance analysis (Quantum X - RJL Systems, Inc., Clinton Township, Michigan)
was used to determine body composition. Measurements were made with patients lying in bed
with 4 electrodes attached to the dorsum of the right hand and foot. Phase angle (PA), fat
mass (FM - kg), fat free mass (FFM, kg), total body water (TBW - L), intracellular water
(ICW - L) and extracellular water (ECW - L), were evaluated.
Resting Energy Expenditure - REE was measured by indirect calorimetry using Quark RMR®
(Cosmed, Rome, Italy). The energy balance (EB) was obtained by subtracting the total energy
expenditure from the total caloric intake (TCI). The total energy expenditure (TEE) was
obtained by multiplying the 24-hour REE by the calculated activity factor (AF), which was
based on the description of the patients' daily activities and the corresponding computed
values of metabolic equivalents (METs). Food intake was assessed by a 3-day food record
(Avanutri Online® (Avanutri Equipamentos de Avaliação Ltda, Rio de Janeiro, Brazil).
Clinical and other variables - Age, sex, etiology, severity of liver disease by the Model
for End Stage Liver Disease score (MELD), complications like presence of fluid retention and
hepatic encephalopathy; number of medication and diuretics; β-blockers and lactulose use
were all compiled. The indications for liver transplantation were categorized into alcoholic
cirrhosis, viral and other diseases.
In the second part of the study the patients evaluated in the pre-transplant who underwent
transplantation were assessed in relation to the same parameters evaluated in the
pre-transplant: nutritional, functional, metabolic, body composition, anthropometric, food
intake and balance energy. For a description of the evolution of variables comparing the
pre- and post-transplantation and evaluate the association of the variables evaluated the
clinical outcomes of patients.
For the study about the prevalence of metabolic changes after liver transplantation in late
post-transplant period, another population was evaluated. Patients undergoing liver
transplantation between the years 2001-2014, which had data in medical records up to at
least one year after surgery were included. To assess the prevalence and factors associated
with hyperkalemia, information collected was: sex, age, underlying disease indication for
transplantation, medication use, potassium, urea, creatinine and sodium values.
Immunosuppressive drugs were: tacrolimus use and dose prescribed, and the residual dose;
cyclosporine use and dose; prednisone use and dose. The use of other drugs included:
furosemide, spironolactone, propranolol, captopril and enalapril.
To assess the prevalence of hypertension, diabetes and overweight according different doses
of immunosuppression the presence of these conditions were collected from diagnosis
described in the medical record of the patient, as well as the use of hypoglycemic agents
and insulin medications will be evaluated; as well as the use of anti-hypertensive drugs. If
the last weight registered in the medical record (post-transplant) subtracted from the
weight recorded in the pre-transplant period will be considered. Those patients record that
had water retention in the preoperative period, the estimated dry weight is considered.
Those patients record that had water retention in the preoperative period, the estimated dry
weight is considered. To do so, it will be contemplated from subtracting the estimated
amount of liquid ascites and / or edema of the then current weight.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02798861 -
Controlled Attenuation Parameter (CAP) in Liver Allografts
|
||
Completed |
NCT01968395 -
Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure
|
Phase 4 | |
Completed |
NCT01437969 -
Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.
|
||
Recruiting |
NCT00155376 -
Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography
|
Phase 4 | |
Recruiting |
NCT00172705 -
Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique
|
N/A | |
Completed |
NCT04185454 -
Estimation of Minimum Efficacy Daily Dose of Jarlsberg Cheese
|
N/A | |
Completed |
NCT02506335 -
Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Heart Disease
|
Early Phase 1 | |
Completed |
NCT02520609 -
Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
|
||
Completed |
NCT02306018 -
Evaluation of a New Calibrated Pulse Wave Analysis Method(EV1000™/volumeView™) for Cardiac Output Monitoring in Adult Liver Transplantation
|
N/A | |
Completed |
NCT01988753 -
Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
|
||
Completed |
NCT01970904 -
Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients
|
N/A | |
Terminated |
NCT00741117 -
Conjugated Hyperbilirubinemia and Pulse Oximetry
|
N/A | |
Enrolling by invitation |
NCT01483248 -
Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis
|
Phase 1/Phase 2 | |
Completed |
NCT00245830 -
Ischemic Preconditioning of Liver in Cadaver Donors
|
N/A | |
Completed |
NCT00074386 -
Kidney and Liver Transplantation in People With HIV
|
N/A | |
Completed |
NCT02329821 -
Change of Lactate Concentration During Hartmann Solution Infusion for Hepatic Resection
|
N/A | |
Completed |
NCT01303549 -
Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients
|
Phase 4 | |
Completed |
NCT01650181 -
Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis
|
Phase 4 | |
Completed |
NCT00799851 -
A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices
|
Phase 4 | |
Completed |
NCT00058890 -
Gabapentin to Treat Itch in Patients With Liver Disease
|
Phase 3 |